osimertinib mesylate

targets

all catalysts(0)

nothing on the calendar yet

News(10)

• Rare EGFR mutation increases lung cancer risk 62 times in never smokers
  A rare inherited germline mutation was found to increase risk for lung cancer by 25 times, while smoking only increased risk by 4 times.
  fiercebiotech · 17d ago
• WCLC ‘26: A new ‘ADC era,’ China questions and AstraZeneca’s spotlight
  The year’s biggest meeting on lung cancer research featured data suggesting a new treatment standard for an aggressive tumor as well as debate about the reliability of results from China-run studies.
  biopharma_dive · 19d ago
• Cullinan, Taiho showcase 6-month survival benefit in phase 3 trial for advanced lung cancer
  Cullinan Therapeutics and Taiho Oncology unveiled phase 3 data showing survival improvements greater than Johnson & Johnson’s Rybrevant in patients with advanced non-small cell lung cancer in the f…
  fiercebiotech · 23d ago
• GSK pens $1.3B Hutchmed deal for early-stage KRAS-EGFR cancer asset
  GSK is handing over $110 million upfront to Hutchmed in a deal worth up to $1.295 billion to get its hands on a first-in-class oncology candidate.
  fiercebiotech · 1mo ago
• AstraZeneca scores in lung cancer; Sandoz inks a China deal
  A combination of AstraZeneca’s Tagrisso and Hutchmed’s Orpathys extended survival for some lung cancer patients. Elsewhere, MapLight floated the idea of partnering on its autism drug.
  biopharma_dive · 1mo ago
• AstraZeneca touts separate late-stage lung cancer wins with Tagrisso, Enhertu
  AstraZeneca on Monday reported successes in two late-stage trials in different forms of lung cancer — one with a two-drug combination of Tagrisso and Orpathys and another with its blockbuster antib…
  endpoints · 1mo ago
• New Taiho, Cullinan data heats up lung cancer drug battle
  The findings position their drug, zipalertinib, as a threat to multiple approved medicines — while setting a bar for others in testing.
  biopharma_dive · 1mo ago
• BlossomHill, Latigo outshine IPO expectations with oversubscribed debuts
  Two growing biotechs blasted through their IPO expectations Friday, with Blossom Hill Therapeutics and Latigo Biotherapeutics each raising at least 30% more than expected in their stock market debuts.
  fiercebiotech · 1mo ago
• Latigo laces up for $247M IPO to fund non-opioid pain drug rival to Vertex’s Journavx
  Latigo Biotherapeutics has fleshed out its plans for an IPO to finance the development of its clinical-stage pipeline of non-opioid pain management drugs.
  fiercebiotech · 2mo ago
• ‘Unlikely’ AstraZeneca-BMS mega-merger would be largest pharma deal ever
  If AstraZeneca and Bristol Myers Squibb were to successfully become one company, analysts say it could reset the current deal environment, which has picked up greatly in the first half of the year.
  biospace · 2mo ago